Quantcast
Last updated on April 17, 2014 at 7:54 EDT

Latest HeartWare International Inc. Stories

2011-01-24 15:44:00

FRAMINGHAM, Mass. and SYDNEY, Jan. 24, 2011 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a third allotment, of 94 additional patients, in its "ADVANCE"...

2011-01-04 16:58:00

FRAMINGHAM, Mass. and SYDNEY, Jan. 4, 2011 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the 29th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. Pacific Time on Monday, January 10, 2011. The conference is being held January...

2010-12-28 06:50:00

FRAMINGHAM, Mass. and SYDNEY, Dec. 28, 2010 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) today announced that it has submitted a Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the HeartWare® Ventricular Assist System as a bridge to heart transplantation for patients with end-stage heart failure. The PMA submission includes data from HeartWare's pivotal ADVANCE clinical trial, an FDA approved IDE study...

2010-12-15 11:34:00

FRAMINGHAM, Mass. and SYDNEY, Dec. 15, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the completion of a public offering of $143.75 million principal amount of convertible senior notes due 2017 (the "notes"), pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on December 9, 2010. This amount includes $18.75 million aggregate principal amount of notes sold...

2010-12-10 06:38:00

FRAMINGHAM, Mass. and SYDNEY, Dec. 10, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") yesterday. HeartWare announced today that it increased its previously announced offering of convertible...

2010-12-09 05:39:00

FRAMINGHAM, Mass. and SYDNEY, Dec. 9, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. HeartWare also intends to grant the underwriters an option to purchase up...

2010-12-02 15:39:00

FRAMINGHAM, Mass. and SYDNEY, Dec. 2, 2010 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Canaccord Genuity Cardio/Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time)....

2010-11-18 16:18:00

FRAMINGHAM, Mass. and SYDNEY, Nov. 18, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the 22nd Annual Piper Jaffray Health Care Conference on Tuesday, November 30, at 3:00 pm EST. The conference is being held...

2010-11-14 08:00:00

FRAMINGHAM, Mass. and SYDNEY, Nov. 14, 2010 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that data from its pivotal bridge to heart transplantation (BTT) study, ADVANCE, showed that 92% of the investigational device patients met the per protocol primary endpoint of the trial, which was...

2010-11-11 15:30:00

FRAMINGHAM, Mass. and SYDNEY, Nov. 11, 2010 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, at 1:15 pm EST. The conference will be held November...